About Repros
Company Overview
Board of Directors and Management
Pipeline
Proellex
®
Anemia Associated with Uterine Fibroids
Uterine Fibroids
Endometriosis
Publications
Androxal
®
Male Fertility Maintenance/Improvement
Metabolic Syndrome
Publications
Clinical Trials
Proellex® Uterine Fibroids (ZPU-301)
Proellex® Endometriosis (ZPE-201)
Proellex® PK Bridging (ZP-002)
Proellex® Safety and PK (ZP-003)
Investors & Media
Events, Presentations and Webcasts
Repros in the News
Major Holders
Analyst Coverage
SEC Filings
Corporate Governance
Contact Us
June 30, 2008
Repros Therapeutics Inc. Initiates a Comparative Phase 2b Study of Oral Androxal® as Compared to Topical Testim® Examining Effects on Male Fertility and Testicular Function
June 9, 2008
Repros Therapeutics Inc. Announces That Initial Findings for Proellex® Show No Gross Cancer Tumors in First Completed Animal Carcinogenicity Study
May 29, 2008
Repros Therapeutics Inc. Announces That Initial Findings for Proellex® Show No Adverse Effects on the Endometrium after One Year on Drug
May 27, 2008
Repros Presentation to Be Webcast from the FBR Capital Markets' 12th Annual Spring Investor Conference
July 24, 2008
Repros Therapeutics Analyst Day
May 29, 2008
FBR 12th Annual Spring Investor Conference
May 14, 2008
Annual Meeting of Shareholders in New York City, NY
May 12, 2008
Repros Shareholder Update Conference Call
Terms of Use
© Repros Therapeutics Inc. All rights reserved.
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax
